Finasteride

A consensus of experts identified seven recommended interventions for AGA, including oral and topical finasteride, dutasteride, and minoxidil, while identifying 17 interventions that are not recommended.

Dutasteride (0.5 mg and 2.5 mg) is significantly more effective than finasteride (1 mg) at increasing hair counts in both males and females with AGA.

The review discusses the potential of topical dutasteride and nanocarrier delivery systems to provide an effective alternative to oral treatments while minimizing systemic absorption.

The review summarizes that finasteride and minoxidil are the primary approved treatments, while noting ongoing development of drugs targeting inflammation, fibrosis, and energy metabolism.

The review summarizes the potential of various herbal compounds, specifically highlighting rosemary oil as a promising natural alternative for managing androgenetic alopecia.

Various over-the-counter, prescription, and procedural treatments successfully promote hair growth, suggesting that a multifaceted, individualized approach is most effective.

Low-dose oral minoxidil has demonstrated a favorable efficacy and safety profile for both male and female androgenetic alopecia.

The paper outlines standard treatments for different alopecia types, noting minoxidil as first-line for androgenetic alopecia and various therapies for focal hair loss.

Various treatments including 5-alpha reductase inhibitors, oral minoxidil, and PRP show efficacy, though evidence for some newer or non-pharmacological methods remains limited.

Standard treatments like topical minoxidil and oral finasteride are established, while newer modalities like PRP, LLLT, and oral minoxidil show encouraging results but lack standardized protocols.

The review provides an update on FDA-approved treatments (minoxidil and finasteride) as well as various non-FDA-approved, emerging, and alternative therapies for AGA.

The review discusses various promising topical, oral, and energy-based therapies, noting growing evidence for their efficacy in treating hair loss.

Natural products such as saw palmetto, caffeine, and rosemary oil may serve as alternatives or adjuncts to conventional minoxidil and finasteride treatments for male AGA.

The review outlines various current and emerging therapies for hair loss, including pharmacological agents, devices, and cellular therapies.

Topical finasteride (0.25% spray or 1% gel) demonstrates efficacy similar to 1 mg oral finasteride in increasing hair density and inhibiting plasma DHT.

Topical finasteride significantly increases target area hair count compared to placebo, with efficacy numerically similar to oral finasteride but with much lower systemic DHT reduction.

Finasteride 1mg/day significantly increases total hair count compared to placebo at both 24 and 48 weeks, with no significant difference in efficacy between 1mg, 5mg, and 1% topical doses.

Dutasteride 0.5 mg/d is ranked as the most effective treatment, followed by higher doses of finasteride and minoxidil.

Topical finasteride, ketoconazole, and C17P show promise for male pattern hair loss, with topical finasteride particularly effective when combined with minoxidil. C17P shows potential for acne vulgaris.

The review outlines various FDA-approved and non-FDA-approved therapies for AGA, emphasizing that treatment selection must balance efficacy, side effects, compliance, and cost.

Combined finasteride and topical minoxidil therapy yields better overall photographic assessment and more marked improvement compared with either monotherapy, while showing similar rates of moderate/mild improvement, hair density change, and adverse events.

The review concludes that finasteride and dutasteride can cause persistent sexual, neurological, and physical side effects in a subset of men, constituting post-finasteride syndrome, for which no evidence-based treatments currently exist.

Finasteride and minoxidil can halt disease progression but only yield partial hair regrowth; early initiation improves outcomes, and PRP may be considered for patients unresponsive to medical therapy.

Herbal drugs may reduce hair loss by inhibiting the 5-alpha-reductase enzyme with potentially fewer side effects than conventional pharmacological treatments.

The meta-analysis found that treatment with finasteride or dutasteride for male androgenetic alopecia is associated with an increased risk of sexual dysfunction, with finasteride showing a statistically significant 66% higher risk compared to placebo, while dutasteride showed a non-significant 37% increase.

First-line therapies recommended include oral finasteride 1 mg daily, oral dutasteride 0.5 mg daily, topical 5% minoxidil twice daily for MPHL and topical 1% minoxidil twice daily for FPHL, along with low-level laser therapy and hair transplantation.

The review highlights several emerging therapies, including novel excipients for oral minoxidil, dutasteride, and finasteride; topical prostaglandin modulators; low-level laser therapy; Wnt pathway activators and stem cell treatments for androgenetic alopecia; JAK inhibitors for alopecia areata; antiandrogens and pioglitazone for frontal fibrosing alopecia; and robotic-assisted follicular unit extraction for hair transplantation.

Minoxidil, finasteride, and low-level laser therapy were significantly more effective than placebo for promoting hair growth in men with androgenetic alopecia, and minoxidil was effective in women.

Treatments such as topical minoxidil and 5‑alpha reductase inhibitors (finasteride, dutasteride) can slow hair loss progression and promote regrowth, but continuous use is required to maintain benefit.

Dutasteride 0.5 mg significantly increased hair count and width and improved hair growth compared to both finasteride 1 mg and placebo.